Invivyd Q1 Revenue Grows 22% but Remains Modest; VYD2311 Safety Signal Positive

What happened

Invivyd reported Q1 2026 PEMGARDA net product revenue of $13.7M, up 22% YoY, but still well below the initial commercial targets set for 2024. Operating expenses rose due to the VYD2311 pivotal program, for which top-line data is expected in Q3 2026. An IDMC ad hoc review recommended reducing post-dose monitoring time for VYD2311 from two hours to 30 minutes, a modest safety vote of confidence. The company ended the quarter with $184.2M cash, supplemented by $20M from an ATM facility in April, providing runway through upcoming catalysts. However, revenue growth remains gradual, and the competitive overhang from AstraZeneca's sipavibart persists, leaving the investment case balanced.

Implication

The 22% YoY revenue growth for PEMGARDA shows some commercial traction, but at a $13.7M quarterly run-rate, the company is still far from the $150-200M annual target it previously touted. The IDMC recommendation to shorten VYD2311 monitoring time is a positive safety indicator, but it does not address efficacy or competitive differentiation versus sipavibart. Cash of $204M (including April ATM) provides through Q3 2026 data readout, but burn rates remain elevated due to pivotal trial costs. Investors should closely watch Q3 2026 VYD2311 data for signs of superior potency or convenience; until then, the stock lacks a clear catalyst. With AstraZeneca's sipavibart advancing and EUA susceptibility thresholds a constant risk, Invivyd remains a speculative hold rather than a clear buy.

Thesis delta

The Q1 2026 revenue beat is a positive data point, but the growth trajectory remains underwhelming relative to initial expectations. The VYD2311 safety update from the IDMC is a minor positive, but the key catalyst remains Q3 2026 efficacy data. Overall, the thesis is unchanged: hold pending clearer evidence of a commercial inflection or competitive advantage.